HuH-7 Xenograft Model Service for Liver Cancer

The HuH-7 cell line serves as a highly reliable and extensively validated in vivo platform for investigating the molecular mechanisms and therapeutic vulnerabilities of hepatocellular carcinoma (HCC). As a specialized pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision HuH-7 Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your liver cancer drug discovery and development pipeline.

Overview of HuH-7 Xenograft Model for Liver Cancer

The HuH-7 xenograft model is an established in vivo translational system widely utilized in oncology research for the study of primary liver malignancy. By transplanting human HuH-7 carcinoma cells into immunodeficient rodent hosts, this model effectively reproduces the solid tumor growth characteristics, histopathological structure, and proliferative profiles representative of human hepatocellular carcinoma.

Biologically, the HuH-7 model is valued for its reliable tumor-take rates and well-characterized growth kinetics, which facilitate the consistent assessment of pharmacological interventions. This model retains essential phenotypic features of human liver cancer, including high mitotic indices and complex intracellular signaling network responses to anti-neoplastic agents. Consequently, the HuH-7 model is extensively deployed in pre-clinical screening programs to assess the potency of novel small-molecule inhibitors, targeted biological therapies, and combination treatment regimens in a physiologically relevant in vivo setting.

Fig 1. CLSM images of Huh-7 and LO2 cells incubated with GPDC-MSNs, PDC-MSNs, and GP-MSNs with or without galactose ligand inhibition. (Li Y., et al., 2020)

Cell Line Information: HuH-7

The HuH-7 cell line is derived from human hepatocellular carcinoma tissue. These cells demonstrate consistent growth characteristics in vitro, making them a stable and preferred choice for developing reproducible xenograft models in liver cancer research.

Our Services

Workflow of HuH-7 Xenograft Model Construction

• Cell Culture & Quality Control: Human HuH-7 cells are expanded in vitro using certified nutrient media under optimized physiological conditions. STR authentication and mycoplasma screening are performed prior to inoculation to ensure absolute genetic integrity and purity.
• Host Selection & Preparation: Immunodeficient mice (e.g., BALB/c nude or NCG) are sourced from validated vendors and undergo an acclimatization phase to stabilize baseline biological metrics before use.
• Precision Inoculation: High-viability HuH-7 cells are prepared in a sterile physiological buffer, optionally supplemented with an extracellular matrix (e.g., Matrigel) to optimize take efficiency. Cells are inoculated in vivo via subcutaneous injection into the host flank to facilitate the development of a measurable, solid tumor.
• Longitudinal Monitoring: Tumor size is measured systematically using digital calipers to monitor volume progression. Animal health, activity, and body weight are recorded periodically to document systemic tolerance and clinical status.
• Randomization & Treatment: Once solid tumors reach a predefined, statistically significant volume, animals are randomized into matched cohorts to ensure parity before the initiation of customized therapeutic dosing regimens.

Fig 2. HuH-7 Xenograft Model Construction Workflow

Case Study - HuH-7 Xenograft Model Development

A pre-clinical validation study was conducted using the HuH-7 xenograft model to evaluate the therapeutic efficacy of a novel anti-HCC candidate. Following the successful subcutaneous inoculation of HuH-7 cells into immunodeficient mice, the host animals developed firm, rapidly growing solid tumors. The treatment group demonstrated a clear, statistically significant inhibition of tumor growth compared to the vehicle-treated control group, confirming the model's high sensitivity and predictive reliability for screening novel liver cancer interventions.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing diverse solid tumor lineages, providing highly reproducible in vivo translational platforms for liver cancer research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive tumor growth metrics and statistical validations.

Contact us

Accelerating your liver cancer drug pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our HuH-7 platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.